Compare Ascendis Pharma A/S (ASND) vs Expensify Inc (EXFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Expensify Inc — how do they compare? Ascendis Pharma A/S trades at $265.33 (market cap $17.74B), while Expensify Inc trades at $1.77 (market cap $182.27M). The key difference: Ascendis Pharma A/S is far larger — about 97.3× Expensify Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Expensify Inc nearer its low. Which is the better fit depends on your goals.
| ASND | EXFY | |
|---|---|---|
Market Cap | $17.74B | $182.27M |
Sector | Health | Technology |
52-Week High | $277.18 | $2.33 |
52-Week Low | $163.32 | $0.75 |
Enterprise Value | $18.11B | $121.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
EXFY trades at $1.89, down 3.08% today, with a bullish technical signal from moving averages and oscillators. The company reported Q1 2026 EPS of $0.04, beating expectations, but maintains negative net income margins. Recent news highlights AI expansion and a $25 million stock buyback program, indicating management confidence despite financial challenges.
Outlook remains mixed with strong analyst buy ratings (44%) but persistent profitability issues. Key opportunities include AI product growth and cash flow stability, while risks involve sustained losses and competitive pressures. The stock presents a speculative opportunity with high volatility potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →
